Windtree Therapeutics (NSDQ:WINT) said today that a preclinical influenza study demonstrated that its aerosolized KL4 surfactant reduced lung inflammation and improved overall survival in ferrets.
In the preclinical study, researchers compared Windtree’s aerosolized KL4 surfactant with a daily oral dose of oseltamivir, an antiviral, and placebo controls. Following exposure to the influenza virus, investigators evaluated the ferrets for clinical signs of infection and lung histopathology changes.
Get the full story at our sister site, Drug Delivery Business News.
The post Windtree touts preclinical data from influenza study for aerosolized surfactant appeared first on MassDevice.
from MassDevice http://ift.tt/2kv1fuh
Cap comentari:
Publica un comentari a l'entrada